相关实验视频

Updated: May 10, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

基于预测器的输出反控制带有正输入的瘤生长:适用于抗血管生成疗法

Mohamadreza Homayounzade¹

¹Department of Mechanical Engineering, Fasa University, Fasa, Iran.

IET systems biology

|April 24, 2025

概括

这项研究引入了一个新的控制系统来管理瘤生长,克服了测量延迟和积极输入约束等挑战. 这种新的方法确保了系统的稳定性和有效的瘤控制.

科学领域:

生物医学工程生物医学工程
控制系统理论控制系统理论
数学瘤学数学瘤学

背景情况:

由于正输入限制和测量延迟,瘤生长控制是复杂的.
传统的控制方法往往是无效的,因为它们无法处理这些生物系统的限制.
系统不稳定性可能来自于闭环系统的输出测量延迟.

研究的目的:

开发一种针对瘤生长的新型控制系统,以解决输入限制和测量延迟的问题.
确保瘤生长控制系统的非对称稳定性.
通过数值比较验证拟议的控制策略的有效性.

主要方法:

开发一个利用延迟输出测量的系统状态预测观察器.
在设计反控制器时应用一个后退技术.
确保控制输入的积极性,以保持系统稳定性.

主要成果:

拟议的控制系统有效地管理瘤生长模型中的延迟和积极输入约束.
后退控制器保证了闭环系统的非对称稳定性.
数字模拟证明了拟议的战略优于现有方法的优势.

结论:

新的控制系统为瘤生长调节提供了强大的解决方案.
状态预测观察员和正约束控制器的集成是有效的.
这种方法提升了精确和稳定的瘤治疗策略的潜力.

关键词:

抗血管性疗法是一种抗血管性疗法.输出反控制输出反控制积极的输入是积极的输入.稳定性分析分析稳定性分析时间延迟系统的时间延迟系统控制瘤生长控制瘤生长

更多相关视频

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Published on: April 16, 2019

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...